AAV-alpha-synuclein: a new tool to study Parkinson’s disease

old_uid13018
titleAAV-alpha-synuclein: a new tool to study Parkinson’s disease
start_date2013/11/15
schedule11h30
onlineno
detailsSéminaire FBN. Une invitation d’Erwan Bézard, directeur de l'IMN
summaryHistological and genetic observations strongly suggest a key role of alpha-synuclein in Parkinson’s disease (PD) pathology. Based on these evidences, we have generated a novel model of PD that replicates essential features of the human condition, i.e the progressive loss of nigral dopamine neurons and the presence of alpha-synuclein pathology. This pre-clinical model is thereby an interesting tool to study stage-dependent pathogenic mechanisms and identify possible targets for therapeutic interventions. The seminar will give an overview of this in vivo model and will show how alpha-synuclein can interfere with key transcription factors to disrupt major survival pathways.
responsiblesDeris